drugset
drugset / Trial / NCT03771157

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157 ↗

Phase 0 Completed 33 enrolled University of Rochester GlaxoSmithKline · collab
NaSingle-groupOpen-labelSupportive care

Summary

The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.

Timeline

Start
2019-02-01
Primary completion
2020-09-01
Completion
2022-08-03

Drugs

EvaluationDrugModalityDoseRoute
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine — Intramuscular

Indications

B-cell chronic lymphocytic leukemia Waldenstrom macroglobulinemia